Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.

Please select an option:

Our portfolio  

High-quality portfolio

A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients’ journeys

Foundation Medicine’s portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys:1–8

Solid tumourTissue sampleBlood sample





All of Foundation Medicine’s services use our leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients’ treatment options.1,2,4,5,7–13

Genomic database

As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: 
    https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020).
  4. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
  5. Data on file: Clinical and analytical validation data file for FoundationOne Liquid CDx.
  6. FoundationOne Liquid CDx FDA Approval, 2020. Available at: www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
  7. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  8. He J et al. Blood 2016; 127: 3004–3014.
  9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  11. Ross JS et al. Cancer 2016; 122: 2654–2662.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  14. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed August 2020).